Vaccine candidate against COVID-19
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Viral vector |
| Clinical data | |
| Routes of administration | Intramuscular |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
|
Medical response |
|
 COVID-19 portal |
AdCLD-CoV19 is a COVID-19 vaccine candidate developed by Cellid Co,[1][2] a company from South Korea.[3]
A phase 1/2 trial of a single injection of AdCLD-CoV19 began in December 2020 in South Korea.[4] In September 2021, a phase 1 trial began for a single injection of another version, named AdCLD-CoV19-1.[5] Preclinical studies of a single dose in mice and non-human primates for this vaccine candidate were published in April 2022.[6] In August 2022, a phase 2 trial of 1 or 2 doses of AdCLD-CoV19-1 was registered.[7]
References
- ^ Chan-Hyuk K (10 December 2020). "LG Chem pushes for Covid-19 vaccine CMO deal". Korea Biomedical Review. Retrieved 22 August 2021.
- ^ Chan-hyuk K (11 August 2021). "Covid-19 vaccine trials stalled by rare chance to get licensed vaccines". Korea Biomedical Review. Retrieved 22 August 2021.
- ^ "Cellid Co Ltd, Company Profile and News". Bloomberg Markets.
- ^ Clinical trial number NCT04666012 for "Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers" at ClinicalTrials.gov
- ^ Cellid Co (21 January 2022). "A Dose Escalation, Multicenter, Open, Phase I Study to Assess the Safety and Immunogenicity of AdCLD-CoV19-1, a COVID-19 Preventive Vaccine in Healthy Volunteers". clinicaltrials.gov. National Institutes of Health. Retrieved 27 September 2022.
- ^ Shin SP, Shin KS, Lee JM, Jung IK, Koo J, Lee SW, et al. (April 2022). "The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates". Vaccines. 10 (5): 712. doi:10.3390/vaccines10050712. PMC 9147121. PMID 35632468.
- ^ Cellid Co (27 August 2022). "A Phase IIb, Multicenter, Observer-Blinded, Randomized, Placebo-Controlled Trial to Evaluate the Immunogenicity and Safety of the AdCLD-CoV19-1 in Healthy Adults Aged 19 Years Old and Above". clinicaltrials.gov. National Institutes of Health. Retrieved 27 September 2022.
Scholia has a profile for AdCLD-CoV19 (Q108415181).
| Development | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||
 | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 28 February 2024, at 11:09